title: The suppression of postoperative liver metastasis caused by the continuous intraportal infusion of angiogenesis inhibitor FR-118487 in a rabbit colon cancer model.
abstract: The inhibitory effect of FR-118487, a potent angiogenesis inhibitor, on neovascularization induced by the VX2 tumor was confirmed in a rabbit corneal assay. The antimetastatic effect of FR-118487 was also investigated in 21 rabbits. Spontaneous liver metastases were induced by VX2 tumor cell implantation into the ascending colonic wall. FR-118487 was then infused continuously into the portal vein for 7 days after resection of the primary lesion at a dose of 1 mg/kg/day (FR-1 group) or 3 mg/kg/day (FR-3 group). The incidence of liver metastases was 71.4%, occurring in 5 of 7 rabbits, in each of the FR-1 and FR-3 groups, compared with 100%, being all of 7 rabbits, in the control group. The number of metastatic foci tended to be less in the FR-1 (31.0 +/- 36.0) and FR-3 (24.6 +/- 45.1) groups than in the control group (83.7 +/- 73.9) and the weight of metastatic foci was significantly less in the FR-1 (1.4 +/- 1.8 g) and FR-3 (1.3 +/- 2.0 g) groups than in the control group (6.5 +/- 4.9 g) (P < 0.05). However, leakage of the colonic anastomosis and body weight loss were limited to the FR-3 group. These results suggest that the continuous intraportal infusion of FR-118487 at 1 mg/kg/day suppressed liver metastases by inhibiting angiogenesis, without producing any adverse effects.
authors.affiliation: Department of Surgery II, Okayama University School of Medicine, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Eda
authors.forename: H
authors.initials: H
authors.lastname: Soga
authors.forename: M
authors.initials: M
authors.lastname: Ueoka
authors.forename: A
authors.initials: A
authors.lastname: Okada
authors.forename: K
authors.initials: K
authors.lastname: Yamashita
authors.forename: N
authors.initials: N
authors.lastname: Shimizu
mesh_terms: D000818:Animals; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000473:pathology*; D004195:Disease Models, Animal; D005260:Female; D007262:Infusions, Intravenous; D008113:Liver Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D011817:Rabbits; D013141:Spiro Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: C096036:FR 118487; D013141:Spiro Compounds